BYRYZN · Rejuran · Re2O — how to choose among three skin boosters in Daegu
Most skin booster comparisons line up product names side by side. But the three products do different jobs inside the skin. One places a material that holds water, one creates a recovery environment, and one supplies material directly. The way to choose comes from that difference.
The short answer
BYRYZN, Rejuran and Re2O are chosen not by ranking but by what each does. If you want to address texture and hydration relatively quickly, or start with a reversible material, we consider BYRYZN (cross-linked hyaluronic acid) first; to address the recovery environment of skin that has become thin and reactive, Rejuran (PN); if density has broken down and material itself is needed, Re2O (hADM). No study compares the three directly, and none of them solves a sagging contour or major volume loss.
What do the three products do inside the skin?
| Item | BYRYZN | Rejuran HB PLUS | Re2O |
|---|---|---|---|
| Class | Cross-linked hyaluronic acid + lidocaine | PN (polynucleotides) + HA + lidocaine | hADM (human acellular dermal matrix) |
| What it does | Places a water-binding material directly | Creates an environment in which skin recovers well | Directly supplies lost material |
| Raw material | Hyaluronic acid (not derived from human or animal tissue) | Purified DNA from salmonid fish | Donated human skin (cells and DNA removed) |
| When change is felt | Tends to be felt early | Usually from around the second session | Gradually, over several weeks |
| Reversal | Possible with hyaluronidase | Not applicable | Not possible |
| Manufacturer | ACROSS (Hugel brand) | PharmaResearch | L&C Bio |
None of the three fills volume or lifts sagging. If the cheeks or temples are hollow, fillers or CaHA; if the jawline sags, lifting devices are the direction that fits.
How far does the evidence go?
| Product | Evidence | Limits |
|---|---|---|
| BYRYZN | Pilot naming the product: 20 people · three sessions · 12 weeks; wrinkles about 40% lower at week 8 | No control group · no data beyond 12 weeks |
| Rejuran | Reviews and expert consensus literature on the PN class; 2026 literature on HA and PN under the eyes | Reviews point out the evidence grade and limitations of the PN class as a whole |
| Re2O | Split-face double-blind randomised trial, 20 people · 20 weeks (control: hyaluronic acid) | Exploratory in scale · mainly instrument-measured endpoints |
No study has compared the three products directly under the same conditions. So there is no sentence in this column saying “this product works better”. The designs of the evidence also differ, so BYRYZN’s 40% and Re2O’s split-face result cannot be set side by side to rank them.
Which we consider first, by concern
| Concern | Consider first | Why |
|---|---|---|
| Rough texture, inner tightness and dullness; want to feel a change quickly | BYRYZN | A water-binding material acts straight away |
| First booster, and you want a reversible material | BYRYZN | Can be broken down with hyaluronidase |
| Thin, reactive skin; slow recovery after laser | Rejuran | Addresses the recovery environment |
| Overall density and firmness have broken down | Re2O | Supplies the material itself |
| Uncomfortable with a raw material of human origin | BYRYZN or Rejuran | Classes not of human origin |
| Thin areas such as around the eyes | CellREDM (hADM) or Rejuran | Fine particles · no volume |
Which treatment is right is decided not by the product but by what your skin has lost and what it still has.
Using them together, or deciding the order
The three products are closer to treatments with divided jobs than to competitors. For example, a plan that addresses early hydration with BYRYZN and carries the skin’s own recovery forward with Rejuran or Re2O is possible.
- We could not find a randomised comparison showing that combining beats a single product
- Doing several at once makes it impossible to tell what worked, so if there is one cause we start with one
- Study designs differ by product, so there is no “right number of sessions” — we recommend Rejuran as a course of three to four sessions three to four weeks apart, the BYRYZN study used three sessions two weeks apart, and for Re2O we decide from progress
Summary
What is established
- BYRYZN = holds water (cross-linked HA) · Rejuran = environment (PN) · Re2O = material (hADM)
- BYRYZN 20-person pilot (no control group); Re2O 20-person split-face randomised trial
- Only BYRYZN can be reversed
What we could not find
- A study comparing the three products directly
- A randomised comparison showing that combining beats a single product
- Long-term duration for any of the three products
BYRYZN, Rejuran and Re2O: frequently asked questions
Which is best: BYRYZN, Rejuran or Re2O?
No study has compared the three directly, so there is no basis for naming the best. If hydration and reversibility matter, we consider BYRYZN first; for the recovery environment, Rejuran; for supplying material, Re2O.
How are Rejuran and Re2O different?
Rejuran (PN) creates an environment in which the skin recovers well by itself, while Re2O (hADM) puts in the material that makes up the skin. Their raw materials also differ: DNA from salmonid fish, and donated human skin.
Will skin boosters lift a sagging face?
No. None of the three pulls up a sagging contour or fills lost volume. Sagging is the territory of lifting devices, and volume loss of fillers or CaHA.
Can I have several skin boosters together?
A plan with divided jobs is possible, but we could not find a randomised comparison showing that combining beats a single product. To be able to assess what worked, if there is one cause we start with one.
How many skin booster sessions do I need?
It differs by product. We recommend Rejuran as a course of three to four sessions three to four weeks apart; the BYRYZN study used three sessions two weeks apart; and Re2O has no research-established standard number, so we decide from progress.
Read next
Product pages
Product references: BYRYZN · Rejuran · Re2O · Collagen boosters compared
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- BYRYZN human study — Lee JH et al., J Cosmet Dermatol 2024;23(2):409–416, DOI 10.1111/jocd.15944. Prospective · single centre · single-arm pilot, 20 subjects (mean age 54.1), three intradermal injections two weeks apart, 12 weeks of follow-up. Lemperle wrinkle scale 2.60 ± 0.60 → week 8 1.55 ± 0.51 (about a 40% reduction), about 33% maintained at week 12. Transient subcutaneous nodule in one person. No control group.
- Rejuran HB PLUS — manufactured by PharmaResearch; PN + hyaluronic acid + lidocaine; medical device in Korea. A course of three to four sessions three to four weeks apart is Miso Clinic’s recommended design.
- The level of PN evidence — Polynucleotides in Aesthetic Medicine: Current Practices and Perceived Effectiveness, Int J Mol Sci 2024 (evidence grade and limitations) · Expert Perspectives: Evidence-Based Applications of Polynucleotides, Clin Cosmet Investig Dermatol (that PN is not a volumiser).
- Re2O split-face trial — Severance Hospital, Yonsei University; split-face, double-blind randomised trial (NCT07155278), International Journal of Molecular Sciences 2026. 20 subjects · 20 weeks · Re2O on one side, hyaluronic acid on the other. Exploratory in scale.
- Miso Clinic clinical protocols — criteria for indications, design by area, and the explanation and consent process before treatment. The source of the sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.